A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted
radiotherapeutics for the treatment of cancers
Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets.
We have assembled a team of scientists and a network of researchers and clinicians which encompass the breadth and depth of expertise required for success.
Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
Ratio ’s Trillium™ technology is a proprietary and innovative platform
that incorporates a tunable, structural motif enabling our compounds to
reversibly bind to albumin, thereby modulating their pharmacokinetics (PK)
and improving drug availability, tumor delivery, and tumor loading,
while simultaneously reducing the side effects commonly observed with
Ratio ’s Macropa™ technology reflects a proprietary chelator that is used to attach the alpha emitting radionuclide actinium-225 to Trillium™ and other compounds. Its unique chemistry enables ease of manufacture and improves in vivo stability of the resulting compound. Macropa™ can be used with a wide variety of compounds, from small molecules to peptides and even large polypeptides, such as antibodies.
We are an experienced team of scientists, passionate about finding a cure for cancer.
MEET THE TEAM
Strong intellectual property positions across multiple platform technologies.
Field-leading team with strong expertise and long standing and excellent relationships with
Innovative and proprietary PK Modulation technology for the construction of improved therapeutic agents.
Two funded alliances with major pharmaceutical companies for first-in-human trials.